### Contractor Information

<table>
<thead>
<tr>
<th>Contractor Name</th>
<th>Contract Type</th>
<th>Contract Number</th>
<th>Jurisdiction State(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part A</td>
<td>05101 - MAC A</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part B</td>
<td>05102 - MAC B</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part A</td>
<td>05201 - MAC A</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part B</td>
<td>05202 - MAC B</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part A</td>
<td>05301 - MAC A</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part B</td>
<td>05302 - MAC B</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part A</td>
<td>05401 - MAC A</td>
<td>J - 05</td>
</tr>
<tr>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>MAC - Part B</td>
<td>05402 - MAC B</td>
<td>J - 05</td>
</tr>
</tbody>
</table>
**LCD Information**

**Document Information**

- **LCD ID**: L37003
- **Original Effective Date**: For services performed on or after 07/17/2017
- **Revision Effective Date**: N/A
- **Revision Ending Date**: N/A
- **Retirement Date**: N/A
- **Source Proposed LCD**: DL37003
- **Notice Period Start Date**: 06/01/2017
- **Notice Period End Date**: 07/16/2017

AMA CPT / ADA CDT / AHA NUBC Copyright Statement
CPT only copyright 2002-2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association.
CMS National Coverage Policy Title XVIII of the Social Security Act (SSA), §1862(a)(1)(A), states that no Medicare payment shall be made for items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.”

Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

42 Code of Federal Regulations (CFR) §410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

CMS Internet Online Manual Pub. 100-02 (Medicare Benefit Policy Manual), Chapter 15, Section 80, “Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests”

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) “Reporting ICD Diagnosis and Procedure Codes”

Coverage Guidance

**Coverage Indications, Limitations, and/or Medical Necessity**

**Indications and Limitations of Coverage**

Based upon currently available information, HLA-DQB1*06:02 typing (81383) for the diagnosis or management of narcolepsy is considered experimental/investigational/unproven for all populations. Although research suggests a strong association between HLA-DQB1*06:02 and narcolepsy risk, HLA-DQB1*06:02 typing is insufficient to confirm a diagnosis of narcolepsy, rule out a diagnosis of narcolepsy or quantify risk for narcolepsy. Therefore, at this time there is no clinical utility for genetic testing or HLA-DQB1*06:02 typing in the diagnosis or treatment of narcolepsy.

**Background**

Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy (sudden loss of voluntary muscle tone), and uncontrollable sleep episodes. Most cases of narcolepsy are sporadic, with symptoms beginning around the time of adolescence.

According to the International Classification of Sleep Disorders, Third Edition (ICSD-3) and the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-5), narcolepsy is diagnosed by a combination of physical exam, medical history, polysomnogram, multiple sleep latency testing (MSLT), and low CSF hypocretin-1 levels. Current recommended treatment options include stimulants and antidepressants. At this time, treatment is aimed towards the control of symptoms and is not curative.\(^\text{12}\)

Narcolepsy has a multifactorial etiology, likely caused by the interaction between genetic risk factors and environmental exposures. Research efforts to identify the genetic contributors to narcolepsy have focused on an association between certain human leukocyte antigen (HLA) haplotypes and narcolepsy risk. The HLA complex encodes greater than 200 genes responsible for the recognition of foreign antigens. These genes are highly polymorphic, and certain alleles have long been known to confer risk for autoimmune disorders.

A variation of the HLA-DQB1 gene called HLA-DQB1*06:02 has been strongly associated with narcolepsy, particularly in individuals who also have cataplexy and a loss of hypocretins. Several genetic association studies in ethnically diverse populations have found a robust association between narcolepsy and the HLA-DQB1*06:02 allele. However, 15 to 25% of unaffected individuals in the general population also carry this risk haplotype, suggesting that it is necessary but not sufficient for the development of narcolepsy.\(^\text{6}\) Additionally, persons with narcolepsy and cataplexy have been identified without the HLA-DQB1*06:02 marker.\(^\text{4}\) More recent studies further
suggest that predisposition to narcolepsy may be the result of complex genetic associations between multiple risk alleles.\textsuperscript{11}

Despite multiple studies replicating the association between HLA-DQB1*06:02 and narcolepsy in different ethnic groups, the overall contribution of HLA variation to disease risk is low. Monozygotic twin studies have shown only partial concordance (25-31%), indicating that environmental factors play a large role in the etiology of narcolepsy.\textsuperscript{8} Recent studies have suggested that exposure to streptococcus, H1N1, and the H1N1 vaccine may also increase the risk for narcolepsy, specifically among individuals with the HLA-DQB1*06:02 allele.\textsuperscript{3,14,4}

Although research suggests a strong association between HLA-DQB1*06:02 and narcolepsy risk, at this time there is no evidence for any diagnostic utility of HLA typing.\textsuperscript{5}

## Coding Information

### Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

### Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

### CPT/HCPCS Codes

**Group 1 Paragraph:** N/A

**Group 1 Codes:**

- 81383 HLA CLASS II TYPING, HIGH RESOLUTION (IE, ALLELES OR ALLELE GROUPS); ONE ALLELE OR ALLELE GROUP (EG, HLA-DQB1*06:02P), EACH

### ICD-10 Codes that Support Medical Necessity

**Group 1 Paragraph:** N/A

**Group 1 Codes:**

- *(XX000) Not Applicable*

### ICD-10 Codes that DO NOT Support Medical Necessity

**Group 1 Paragraph:** N/A

**Group 1 Codes:**

- G47.411 Narcolepsy with cataplexy
- G47.419 Narcolepsy without cataplexy
- G47.421 Narcolepsy in conditions classified elsewhere with cataplexy
- G47.429 Narcolepsy in conditions classified elsewhere without cataplexy


